Conflict of interest: None.
MAL-PDT for difficult to treat nonmelanoma skin cancer
Article first published online: 30 JAN 2011
© 2011 Wiley Periodicals, Inc.
Volume 24, Issue 1, pages 82–93, January/February 2011
How to Cite
Stebbins, W. G. and Hanke, C. W. (2011), MAL-PDT for difficult to treat nonmelanoma skin cancer. Dermatologic Therapy, 24: 82–93. doi: 10.1111/j.1529-8019.2010.01381.x
- Issue published online: 30 JAN 2011
- Article first published online: 30 JAN 2011
- aminolevulinic acid;
- methyl aminolevulinic acid;
- nonmelanoma skin cancer;
- photodynamic therapy;
With an incidence of over 3.5 million nonmelanoma skin cancers (NMSCs) per year in the United States, there is an increasing need for effective, cost-effective treatments for NMSC. When surgical excision is impractical or not feasible, methyl aminolevulinate photodynamic therapy (MAL-PDT) has demonstrated consistently high long-term cure rates ranging from 70–90%, with superior cosmetic outcomes compared with other treatment modalities. With the exception of invasive squamous cell carcinoma, MAL-PDT has been successful in treating all types of NMSC, especially in patients with multiple comorbidities, field cancerization, and lesions in cosmetically sensitive locations. Herein, a step-by-step description of the procedure for MAL-PDT is provided, followed by a review of outcomes from large clinical trials performed over the past 15 years for each variant of NMSC. After reading this review, clinicians should have a thorough understanding of the benefits and limits of MAL-PDT, and should be able to add this valuable procedure to their armamentarium of therapies for NMSC.